Key result
Ex-vivo Bio-STAR assessment post-stereotactic arrhythmia radiotherapy demonstrates preserved cardiomyocyte viability and isolatability.
Why the study?
Stereotactic arrhythmia radiotherapy is an emerging option for refractory VT, but the underlying myocardial effects in humans remain poorly understood.
Is the Bio-STAR framework feasible for standardized ex-vivo assessment of STAR-treated myocardium in explanted human hearts?
Observational (n=2)
Yes
Is the Bio-STAR framework feasible for standardized ex-vivo assessment of STAR-treated myocardium in explanted human hearts?
The Bio-STAR framework provides a feasible, standardized approach for multimodal ex-vivo analysis of STAR-treated myocardium, enabling future research on radiation effects in human hearts.
Enables standardized human STAR myocardial research; hypothesis-generating and should not yet change practice.
Aims Stereotactic arrhythmia radiotherapy (STAR) is an emerging non-invasive option for refractory ventricular tachycardia (VT), yet the underlying myocardial effects in humans remain poorly understood. Within the STOPSTORM consortium, we developed the Bio-STAR framework for standardized ex-vivo assessment of STAR-treated myocardium, and here report its feasibility and initial findings in human samples. Methods and results Bio-STAR standardizes myocardial sampling into non-irradiated control (NFNI), minimally fibrotic irradiated, and fibrotic irradiated zones, guided by visual inspection, electro-anatomical maps, and radiotherapy dose overlays. Recommended analyses span ex-vivo MRI, histology, immunohistochemistry/-fluorescence, molecular panels, and live-cell assays. Application to two explanted non-ischaemic cardiomyopathy hearts (transplantation 3–5 months post-STAR) confirmed the protocol's applicability to end-stage remodeling. In exploratory analyses of irradiated regions, patient-specific patterns emerged, including stress marker upregulation, and altered NaV1.5, SERCA2a, and CaV1.2 when normalized to cardiomyocyte content. Functional analyses in a limited number of viable cardiomyocytes from the respective regions demonstrated heterogeneous excitability, supporting the feasibility of isolating live cells from STAR-treated regions in which Ca2+ signalling can be quantitatively assessed in future studies involving larger patient cohorts. Conclusion Bio-STAR provides a reproducible framework for multimodal analysis of STAR-treated myocardium, enabling harmonized cross-centre research. Early human data demonstrate that cardiomyocyte viability and isolatability are preserved across all assessed regions, and that STAR-exposed areas may exhibit region-specific structural features, while functional data on Ca2+ handling remain exploratory and require validation in larger datasets. Broad adoption will be key to delineating dose–time–substrate relationships and disentangling radiation effects from underlying cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Nedios et al. (2026) conducted an observational in Refractory ventricular tachycardia (VT) and non-ischaemic cardiomyopathy (n=2). Stereotactic arrhythmia radiotherapy (STAR) and Bio-STAR standardized processing vs. Non-irradiated control zones was evaluated on Feasibility of standardized ex-vivo assessment and cardiomyocyte viability. Standardized ex-vivo assessment using the Bio-STAR framework in 2 explanted hearts post-stereotactic arrhythmia radiotherapy demonstrated preserved cardiomyocyte viability and isolatability.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: